Prostvac-type vaccine therapy in progressive prostate cancer after first-line therapy

A study just published in European Urology has suggested that early therapy with Prostvac-type vaccines might have value in the management of men with a rising PSA after first-line therapy. … READ MORE …

The Prostate Health Cocktail in management of biochemically recurrent prostate cancer

A newly published paper by some highly regarded researchers provides data from a small, Phase II trial of Prostate Health Cocktail (PHC) — an “over-the-counter” combination herbal supplement — in the management of biochemical recurrence of prostate cancer. … READ MORE …

New prostate cancer “vaccine” in Phase II trial prior to ADT

According to a media release we saw this morning, a company called Madison Vaccines has started a Phase II clinical trial of a new form of immunotherapy for treatment of men with non-metastatic prostate cancer and rising PSA levels prior to any treatment with androgen deprivation therapy (ADT). … READ MORE …

Rising PSA levels in non-metastatic prostate cancer

In this month’s online issue of Oncology, you can read a full review by Moul et al. (not just the abstract) addressing the complexities of the management of a rising PSA in men with histologically proven but non-metastatic prostate cancer, i.e., men who have failed definitive therapy for localized disease or men who are initially diagnosed with progressive disease. … READ MORE …